Explore the vast range of titles available.

The anterior pituitary gland is composed of five types of hormone-producing cells and folliculo-stellate cells. Folliculo-stellate cells do not produce anterior pituitary hormones but they are thought to play important roles as stem cells, phagocytes, or supporting cells of hormone-producing cells in the anterior pituitary. S100β protein has been used as a folliculo-stellate cell marker in some animals, including rats. However, since no reliable molecular marker for folliculo-stellate cells has been reported in mice, genetic approaches for the investigation of folliculo-stellate cells in mice are not yet available. Aldolase C/Zebrin II is a brain-type isozyme and is a fructose-1,6-bisphosphate aldolase. In the present study, we first used immunohistochemistry to verify that aldolase C was produced in the anterior pituitary of rats. Moreover, using transgenic rats expressing green fluorescent protein under the control of the S100β gene promoter, we identified aldolase C-immunoreactive signals in folliculo-stellate cells and marginal cells located in the parenchyma of the anterior pituitary and around Rathke’s cleft, respectively. We also identified aldolase C-expressing cells in the mouse pituitary using immunohistochemistry and in situ hybridization. Aldolase C was not produced in any pituitary hormone-producing cells, while aldolase C-immunopositive signal co-localized with E-cadherin- and SOX2-positive cells. Using post-embedding immunoelectron microscopy, aldolase C-immunoreactive products were observed in the cytoplasm of marginal cells and folliculo-stellate cells of the mouse pituitary. Taken together, aldolase C is a common folliculo-stellate cell marker in the anterior pituitary gland of rodents.

Enough is enough Appetite is regulated — at least in part — in the hypothalamus, the brain region that links the nervous and endocrine systems. A screen for appetite-regulating molecules has now identified a fragment of the protein nucleobindin 2, dubbed nesfatin-1, as a satiety molecule produced in the hypothalamus. When nesfatin-1 is injected into the brain, rats eat less and lose weight. When nesfatin-1 is blocked, animals eat more. Nesfatin-1 is therefore a possible target for antiobesity drugs. A secreted protein, nesfatin-1, is expressed in the hypothalamus and induces the feeling of being full. In rats, its injection into the brain decreases food intake, but blocking its action stimulates appetite. The brain hypothalamus contains certain secreted molecules that are important in regulating feeding behaviour 1 , 2 , 3 . Here we show that nesfatin, corresponding to NEFA/nucleobindin2 (NUCB2), a secreted protein of unknown function, is expressed in the appetite-control hypothalamic nuclei in rats. Intracerebroventricular (i.c.v.) injection of NUCB2 reduces feeding. Rat cerebrospinal fluid contains nesfatin-1, an amino-terminal fragment derived from NUCB2, and its expression is decreased in the hypothalamic paraventricular nucleus under starved conditions. I.c.v. injection of nesfatin-1 decreases food intake in a dose-dependent manner, whereas injection of an antibody neutralizing nesfatin-1 stimulates appetite. In contrast, i.c.v. injection of other possible fragments processed from NUCB2 does not promote satiety, and conversion of NUCB2 to nesfatin-1 is necessary to induce feeding suppression. Chronic i.c.v. injection of nesfatin-1 reduces body weight, whereas rats gain body weight after chronic i.c.v. injection of antisense morpholino oligonucleotide against the gene encoding NUCB2. Nesfatin-1-induced anorexia occurs in Zucker rats with a leptin receptor mutation, and an anti-nesfatin-1 antibody does not block leptin-induced anorexia. In contrast, central injection of α-melanocyte-stimulating hormone elevates NUCB2 gene expression in the paraventricular nucleus, and satiety by nesfatin-1 is abolished by an antagonist of the melanocortin-3/4 receptor. We identify nesfatin-1 as a satiety molecule that is associated with melanocortin signalling in the hypothalamus.

Estrous cyclicity is controlled by a cascade of neuroendocrine events, involving the activation of the hypothalamo-pituitary-gonadal axis. Two modes of gonadotropin-releasing hormone (GnRH) are well established to regulate the estrous cycle: one is a tonic or pulse mode of secretion which is responsible for the stimulation of follicular development and steroidogenesis; the other is a surge mode, which is solely responsible for the induction of luteinizing hormone (LH) surges, eventually leading to ovulation. Metastin/kisspeptin-GPR54 signaling has been suggested to control ovarian cyclicity through regulating the two modes of GnRH release. A population of metastin/kisspeptin neurons located in the anteroventral periventricular nucleus (AVPV) is considered to trigger GnRH surge and thus to mediate the estrogen positive feedback action on GnRH release. The other hypothalamic population of metastin/kisspeptin neurons is located in the arcuate nucleus (ARC) and could be involved in generating GnRH pulses and mediating negative feedback action of estrogen on GnRH release. GnRH neurons express mRNA for GPR54, a metastin/kisspeptin receptor, and have a close association with metastin/kisspeptin neurons at the cell body and terminal level, but the precise mechanism by which this peptide regulates the two modes of GnRH release needs to be determined. Metastin/kisspeptin, therefore, is a key hypothalamic neuropeptide, which is placed immediately upstream of GnRH neurons and relays the peripheral steroidal information to GnRH neurons to control estrous cyclicity.

Pituitary embryonic development progresses daily toward terminal differentiation exhibiting quantitative and qualitative alterations regulated by signal molecules and transcription factors expressed under temporospatial control. In this study, we analyzed the heterogeneity of the cells in the pituitary primordium of embryonic day (E) 13.5. The three-dimensional structure of the Rathke’s pouch was built up from measurements taken from multiple DAPI-stained sections and cell populations positive to stem/progenitor marker SOX2 and pituitary-specific transcription factor PROP1 were analyzed. The pituitary primordium (Rathke’s pouch) of E13.5 showed a flattened discoid shape of about 500 μm in diameter and 200 μm depth in a dorsoventral axis and consisted in about 5,800 cells. Immunohistochemistry revealed that 0.3% of the cells in Rathke’s pouch were SOX2-negative in the lateral region, whereas all cells at E12.5 were SOX2-positive. On E13.5, the shape and size of their nuclei showed a location-specific divergence: ellipsoid morphology in the median region and round morphology in the lateral region. Moreover, on E14.5, adrenocorticotropic-hormone-positive cells (the first hormone-producing cells appearing in the pituitary) contained round nuclei. These data suggest that differentiation to pituitary-hormone-producing cells from SOX2-negative cells starts in the lateral region between E12.5 and E13.5 and that the onset of differentiation is preceded by a change in nuclear shape.

We have reported that the unique thyroid-stimulating hormone-immunoreactive cells (TSH cells) in the intact adult and fetal rat pars tuberalis (PT) show an intense spot-like TSH immunoreaction in the perinuclear region. The present study was designed to investigate the relationship between melatonin and these unique TSH cells. We classified TSH cells in the PT (PT-TSH cells), on the basis of immunoreactivity, into spot-like stained cells (SC) and whole cytoplasm stained cells (WC), and estimated the proportion of each TSH cell type to total cells in the experimental rats by morphometry. Chronic administration of melatonin to control rats leads to an increase of WC in number but a decrease of SC. On the other hand, the intensity of TSH immunoreactivity and the number of rat PT-TSH cells significantly decreased after pinealectomy and recovered by melatonin administration. Radioimmunoassay showed that melatonin treatment increased the TSH content in the PT. Moreover, electron microscopy showed that the number of TSH secretory granules in the PT-TSH cells increased in the melatonin-replaced rats. These results demonstrated that melatonin stimulates the accumulation of TSH in the rat PT-TSH cells via secretory granule formation and suggest that melatonin regulates TSH release from PT-TSH cells.

A pituitary tumor is considered to be composed of a heterogeneous population of hormone-producing endocrine cells, folliculo-stellate (FS) cells, and potential hormone-inactive progenitor cells to maintain a microenvironment such as that in angiogenesis for tumor development cooperatively. However, the system that maintains such a heterogeneous cell population has not been clarified yet. In the present study, we examined the mechanism for maintaining a heterogeneous cell population using two rat cell lines, MtT/S and MtT/E cells, which are known growth hormone (GH)-producing cells, and their progenitor cells, respectively. We found that conditioned medium of MtT/S cells could stimulate the growth of MtT/E cells. In addition, GH and insulin-like growth factor I (IGF-I) stimulated the growth of MtT/E cells. The messenger RNAs (mRNAs) of receptors for IGF-I and GH were expressed in the MtT/E cells. Moreover, IGF-I receptor inhibitor AG1024 could abolish the growth stimulatory activity in the conditioned medium of MtT/S cells. Therefore, we concluded that somatotropes (MtT/S) maintain their progenitor cells (MtT/E) through the GH-IGF-I signaling and IGF-I directly, which might be involved in the maintenance of progenitors of GH-producing cells and might contribute to pituitary tumor development.

In previous studies, the distribution of thyrotropes in the chicken pituitary gland has been analyzed by immunohistochemistry using heterologous antibodies. In this study, we examined the distribution of thyroid-stimulating hormone beta subunit-immunopositive (TSHbeta-ip) cells and the expression of TSHbeta mRNA in the pituitary glands of chicken embryos by immunohistochemistry using a specific antiserum to the chicken TSHbeta, in situ hybridization and RT-PCR. Immunohistochemical and morphometric analyses revealed that the TSHbeta-ip cells first appeared on embryonic day 10 (E10) in the pituitary gland and were mainly distributed in the cephalic lobe and that the cell density on E20 was almost 4 times greater than that on E10. The chicken TSHbeta-ip cells could be classified into two types based on morphological characteristics: round-shaped cells and club-shaped cells, which have long cytoplasmic processes. In situ hybridization analysis revealed that TSHbeta mRNA-expressing cells were expressed from E9 in the cephalic lobe and that the extent of TSHbeta mRNA-expressing cells coincided with that of TSHbeta-ip cells. RT-PCR also showed that TSHbeta mRNA was expressed from E9 and that Pit-1 mRNA was expressed from E5. These results clearly demonstrated that the expression of chicken TSHbeta mRNA starts on E9, that TSHbeta-ip cells appear on E10, mainly in the cephalic lobe, and that TSHbeta-ip cells can be classified into two cell types (round- and club-shaped cells).

To study pituitary tumor formation, we used a rat pituitary tumor cell line, MtT/E, which was derived from an estrogen-induced rat prolactinoma. MtT/E cells are known not to produce any pituitary hormone; however, they do produce the Pit-1 protein, which is known to be a common transcription factor in thyrotropes, somatotropes, and mammotropes. Although MtT/E is a clonal cell line, it exhibits two distinct phenotypes, fibroblastic (F-) and epithelial (E-) cells. We obtained subclonal cell lines from MtT/E cells with characters similar to those of F- and E-cells and called them MtT/E-G1 and MtT/E-B3, respectively. To examine tumor formation by these cells, we implanted them into female Fischer rats. One month later, typical pituitary tumors had appeared in MtT/E-B3-implanted rats; however, tumor formation by MtT/E-G1 was delayed. Interestingly, the tumors formed by MtT/E-B3 cells were intensely vascularized. To examine changes in tumor cell morphology, we performed primary culture and found that spindle-shaped cells appeared. These spindle-shaped cells were immunopositive for the Pit-1 protein, which suggests that they originated from MtT/E-B3 cells. Interestingly, reverse transcriptase polymerase chain reaction showed that both tumors and the cells obtained in primary culture expressed basic fibroblast growth factor (bFGF). By contrast, the original MtT/E-B3 cells did not express bFGF. These results suggested that MtT/E-B3 cells show a change in phenotype during tumor formation; that is, epithelial-type cells change into bFGFexpressing fibroblastic cells. These phenomena, especially the appearance of bFGFexpressing cells in tumor tissue, may explain the extensive angiogenesis in the tumors formed by MtT/E-B3 cells.